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REDUCTION OF ACUTE GVHD IN UNRELATED HEMATOPOIETIC STEM
CELL TRANSPLANTATION BY CO-INFUSION OF HAPLOIDENTICAL BONE
MARROW AS THE THIRD PARTY CELLS
Zhao, Y.-L., Gao, Y.-Q., Xiong, M., Zhang, W.-J., Zhou, J.-R., Sun, Y.,
Zhang, Y.-C., Da, W.-M., S.-Q., JiLuD.-P. Beijing Daopei Hospital,
Beijing, China
Acute graft versus host disease (aGVHD) is one of main causes for
morbidity and mortality in unrelated donor hematopoietic stem cell
transplantation (URT). Our previousmurine and clinical studies had
demonstrated that the third party cells could reduce the incidence
and degree of aGVHD. In haploidentical hematopoietic stem cell
transplantation, unrelated cord blood as the third party cells could
significantly reduce the incidence of aGVHD and 100-day trans-
plant-related mortality (Lu DP et al. ASH 2008). In this perspective
pilot study, the safety and efficacy of co-infusion of haploidentical
bone marrow (haplo-BM) in URT were investigated. FromOctober
2008 to June 2010, 18 patients with hematological malignancies who
received URT with haplo-BM co-infusion in Beijing Dao-Pei Hos-
pital were enrolled. Median age of the patients was 25 (9-39) years
old. Diagnosis included AML (n 5 8), ALL (n 5 4), CML (n 5 5)
and SAA(n 5 1). Twelve of 17 patients with malignances were in
CR1 or CP1 before transplant. HLA 10/10 matched was in 6 cases,
9/10matched in 5, and 8/10matched in 7. Conditioning was BU/CY
or CY/TBI plus ATG (5mg/kgX 4, Fresenius). Cyclosporine,MTX,
and MMF were used for GVHD prophylaxis. Haplo-BM (1 ml/kg)
was infused right after URT. Haplo-BM co-infusion had no any
side events. All 18 patients had hematopoietic reconstitution. Full
unrelated donor chimerism was detected by STR PCR in all patients
one month after transplant, and no engraftment of haplo-BM was
found. By October 2010, the median follow-up time was 12.5(3-
23) months. Only one patient developed grade IV aGVHD at day
30, and died of infection 8 months post-URT. The estimated one
year OS and LFS are 92.3%. The other 17 patients had no grade
II-IV aGVHD and are free of their primary diseases. Our prelimi-
nary results show that haplo-BM co-infusion as the third party cell
is safe, convenient and inexpensive. It could reduce the incidence
of aGVHD in URT.386
CLOFARABINE 6 FLUDARABINE AND IV BUSULFAN WITH ALLOGENEIC
STEM CELL TRANSPLANTATION FOR ADVANCED MYELOID LEUKEMIA
(ML) AND MDS
Andersson, B.S.1, Valdez, B.C.1, Thall, P.F.2, Wang, X.2, Worth, L.L.3,
Popat, U.1, Alousi, A.1, Hosing, C.1, Jones, R.B.1, Shpall, E.J.1, de
Lima, M.1, Champlin, R.E.1 1UT MD Anderson Cancer Center,Table 1. Simple and Adjusted Models of Mortality, Hospitalization,
HCT by Pre-transplant Respiratory Virus Status.
Outcome Respiratory Virus HR (
Overall survival No virus (N5338)
All viruses (N5115) 2.1 (1
Group 1 (n571) 2.0 (1
Group 2 (n544) 2.1 (0
Days (
Days alive and out of hospital No virus (N5338)
All viruses (N5115) -9.8 (-1
Group 1 (n571) -9.8 (-1
Group 2 (n544) -9.7 (-1
HR (9
Bronchoscopy incidence No virus (N5338)
All viruses (N5115) 1.6 (1
Group 1 (n571) 1.3 (0
Group 2 (n544) 2.1 (1
*All outcomes adjusted for disease risk. Also adjusted for 1age, stem cell sourHouston, TX; 2UT MD Anderson Cancer Center, Houston, TX; 3UT
MD Anderson Cancer Center, Houston, TX
Clofarabine (Clo), a later generation nucleoside analog (NA), has
much improved antileukemic effects, and it shows synergistic activity
when combined with Fludarabine (Flu) and Busulfan (Bu) under
controlled in vitro conditions. We investigated combinations of
[Clo6Flu] with IV Bu as pretransplant conditioning in patients
with advanced myeloid leukemia and MDS.
Methods: Patients were adaptively randomized based on day +30
disease- and chimerism status: Arm I: Clo:Flu 10:30 mg/m2, Arm
II 20:20 mg/m2, Arm III 30:10 mg/m2, and Arm IV: Clo only at
40 mg/m2. The Clo and Flu were infused over 1 hr each once daily
for 4 days, on each day Bu was given over 3 hr targeting an average
daily AUC of 6,000 mMol-min. GVHD-prophylaxis was tacroli-
mus+mini-MTX. Recipients of unrelated or one Ag-mism related
donor cells received rabbit-ATG at a total dose of 4 mg/kg.
Results: There were 36 males, 20 females, median age was 45 yrs
(range 6-59). 46 had AML (ind. failure: 15, chemo-refr. relapse:
11, untr. relapse: 7, CR2+CR2p: 10, high-risk CR1+CR1p: 3). 23
had intermediate-, one had good- and 21 poor-prognosis cytogenet-
ics, 1 was unknown. 10 had CML (BC: 2, second AP: 4, and late CP
4). 25/56 (44%) had related donors (BM: 6, PBPC: 19), and 31 (55%)
unrelated donors (BM:16, PBPC:15). All patients engrafted. All pa-
tients had 100% (64-100) donor-derived DNA in the T- and mye-
loid-cell populations by day +100. The adaptive randomization
allocated most patients to Arm III, (Clo 30 mg/m2, Flu 10 mg/m2),
consistent with in vitro observed synergy of [Clo+Flu]. 28/33
(85%) transplanted with active AML and 8 of 10 with CML achieved
CR. Median overall survival is 16 months (range 1-45), one-year
overall and event-free survival are 58% and 43%. There were 2 treat-
ment-related deaths by day +100 (4%), one infectious and one of
GVHD.Grade 2-3 mucositis was seen in 80% of patients, but no se-
rious hepatic, renal, or neuro-toxicities were encountered.
We conclude that 1) the immunosuppressive capability of Clofar-
abine supports allogeneic progenitor cell engraftment, 2) Clo6Flu
with IV Bu is safe and efficacious conditioning therapy 3) the adap-
tive randomization favoring Arm III (Clo 30 mg/m2 and Flu 10 mg/
m2) agreed with previously observed in vitro synergy of [Clo+Flu].
Additional patients and longer follow-up are warranted to evaluate
the combined [Clo+Flu] with IV Bu in pretransplant therapy.387
CLINICAL OUTCOMES ASSOCIATED WITH PRE-TRANSPLANTATION RE-
SPIRATORY VIRUS INFECTIONS
Campbell, A.P.1,2,3, Minerich, E.L.1,3, Guthrie, K.A.3, Farney, R.M.3,
Kuypers, J.2,3, Englund, J.A.1,2,3, Boeckh, M.2,3 1Seattle Children’s
Hospital, Seattle, WA; 2University of Washington, Seattle, WA; 3Fred
Hutchinson Cancer Research Center, Seattle, WAand Bronchoscopy Incidence During the First 100 Days After
Unadjusted Adjusted*
95% CI) p-value HR (95% CI)1 p-value
1.0 - 1.0 -
.1 – 3.7) 0.02 2.0 (1.1 – 3.8) 0.02
.0 – 4.0) 0.05 1.9 (1.0 – 4.0) 0.07
.9 – 4.9) 0.07 2.2 (0.9 – 5.2) 0.07
95% CI) p-value Days (95% CI)2 p-value
0 - 0 -
5.3, -4.2) <0.001 -8.7 (-13.9, -3.6) <0.001
6.6, -3.1) 0.004 -8.5 (-14.7, -2.3) 0.008
7.9, -1.4) 0.02 -9.2 (-16.8, -1.5) 0.02
5% CI) p-value HR (95% CI)3 p-value
1.0 - 1.0 -
.0 – 2.5) 0.06 1.4 (0.9 – 2.2) 0.17
.7 – 2.3) 0.43 1.1 (0.6 – 2.1) 0.69
.1 – 3.8) 0.02 1.8 (1.0 – 3.4) 0.05
ce, donor type; 2stem cell source, transplant type; and 3age.
